- Novel system is the first to use rapid, automated DNA sequencing to
perform microbial 'fingerprinting'
NEW YORK, Sept. 5 /PRNewswire/ -- eGenomics, Inc., a leader in the development of state of the art genomic and informational systems for infectious disease control, announced today that the United States Patent and Trademark Office (USPTO) recently issued U.S. Patent no. 7,449,808, for key elements of its proprietary warning system for hospital infection control. The system "fingerprints" infection-causing bacteria using automated DNA sequencing, stores the resulting DNA sequences in a central database and analyzes the results using proprietary algorithms. The platform allows hospital infection control teams to monitor in "real time" the spread of specific harmful pathogens.
"The eGenomics System should be a major component of every hospitals' effort to monitor and prevent methycillin-resistant strains of Staphylococcus aureus (MRSA) infections," comments Barry Kreiswirth, the company's Chief Scientist. "In addition, the eGenomics platform works equally well on all Staphylococcus aureus -- MSSA and MRSA. We are in the process of expanding our monitoring system to work with other common nosocomial pathogens."
The eGenomics 'mapping' system differentiates clusters of related strains in order to identify a source or transmission vector. Importantly, the system can identify when strains are not related, effectively telling a hospital when they are and when they are not experiencing internal transmission problems.
"The eGenomics platform will allow infection control teams to monitor
and prevent potential outbreaks as well as monitor random, non-outbreak
events. It will allow us to focus our infection control efforts on the most
critical areas," observed Dr. Brian Koll, the Chief of Infectious Disease
at Beth Israel Medical Center in New York. "The eGenomics platform also
allows us to monitor which MRSA strains a
|SOURCE eGenomics, Inc.|
Copyright©2008 PR Newswire.
All rights reserved